Curapel is a Cardiff, Wales–based healthcare company spun out of the University of Manchester and led by CEO Dr Peter Luebcke with CTO Dr Neil Gibbs. The company develops treatments for eczema and psoriasis and products for skin pigmentation conditions. Its pipeline includes Histimex (an oral treatment with early clinical potential in eczema and atopic dermatitis, including pediatric eczema), Melidex (a cosmetic product to even skin tone and treat pigmentation), and Olidex (a topical treatment for psoriasis). Products are formulated from safe, natural and GRAS-designated ingredients and are patent protected. All products are in late-stage product development with clinical testing scheduled to continue through 2016. Curapel is using new funding to develop and commercialise the Histimex, Melidex and Olidex product portfolio.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

May 2016